Publications – United Therapeutics Medical Affairs

The following information is limited to United Therapeutics sponsored studies. Information is not intended to offer recommendations for any administration, indication, dosage, or other use inconsistent with approved prescribing information.

Inhaled Treprostinil in Pulmonary Hypertension due to Interstitial Lung Disease

Advance Outcomes – a Phase 3, Randomized, Double-blind, Placebo-controlled study to evaluate the efficacy and safety of ralinepag to improve treatment outcomes in subjects with pulmonary arterial hypertension

Design of ADVANCE CAPACITY: Effects of ralinepag on exercise capacity measured by cardiopulmonary exercise testing.

Real-world transitions from inhaled, parenteral, and oral prostacyclin class agents to oral treprostinil: Interim data from the ADAPT registry

Interim Results from EXPEDITE: A Study of Parenteral Treprostinil Induction Followed by Oral Treprostinil Optimization in Subjects with Pulmonary Arterial Hypertension

Interim data from the ADAPT registry: Real-world tolerability and management of adverse events in patients receiving oral treprostinil

Pharmacokinetics of Oral Treprostinil in Children with Pulmonary Arterial Hypertension

Contemporary dosing characteristics of oral treprostinil in real world clinical practice in patients with pulmonary arterial hypertension

Understanding the Psychological Mindset of People with PAH

Low Utilization of Prostacyclin Therapy Prior to Death Among Medicare Patients With Pulmonary Arterial Hypertension

Development of the Pulmonary Hypertension Functional Class Self-Report (PH-FC-SR)

The Impact of Inhaled Treprostinil on Patient Lung Function – Results from the INCREASE Study

Reasons for Refusing Parenteral Therapy: A Qualitative Study of Patients with Pulmonary Arterial Hypertension

Implantable System for Treprostinil: A Real-World Patient Experience Study

Medication Adherence and Healthcare Costs among Patients Diagnosed with Pulmonary Arterial Hypertension Treated with Oral Prostacyclin-class Therapies: A Retrospective Cohort Study

Baseline Risk Evaluation Predicts Likelihood of Clinical Worsening: A Sample Size Re-analysis from Freedom-EV

Treatment with Oral Treprostinil Improves Hemodynamics in PAH: FREEDOM-EV

Do Plasma Metabolomic Profiles Differentiate Responders from Nonresponders to Oral Treprostinil? Results from the FREEDOM Phase 3 Clinical Development Program

Novel dose-response analyses of treprostinil in pulmonary arterial hypertension and its effects on 6-minute walk distance and hospitalizations

The Impact of Stratification by Baseline Pulmonary Arterial Hypertension Risk Score – Analysis from the FREEDOM-EV Study

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial

Inhaled Treprostinil in Interstitial Lung Disease Associated Pulmonary Hypertension: The INCREASE Study

An Analysis of FREEDOM-EV Using the French Noninvasive and REVEAL 2.0 Risk Stratification Criteria

Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure

Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial

Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension: A Double-Blind, Placebo-Controlled Study

Long term oral treprostinil use in prospective studies: dosing, tolerability, and pharmacokinetics – substudy to evaluate pharmacokinetics and adverse events in patients transitioning from twice daily to three times daily dosing

The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension

Effect of esuberaprost on morbidity and mortality in World Health Organization (WHO) Functional Class (FC) III and IV Patients with pulmonary arterial hypertension (PAH): Results from the randomized, double-blind, placebo-controlled Phase 3 Trial- Beraprost-314d Added to Tyvaso (BEAT)

Survival and drug persistence in patients with pulmonary arterial hypertension receiving inhaled treprostinil at doses greater than 54 mcg (9 breaths) 4 times daily

Real-world characteristics of patients initiating oral treprostinil in the ADAPT registry: interim baseline characteristics

Treatment benefits associated with open label oral treprostinil after clinical worsening in the phase 3 FREEDOM-EV study for the treatment of pulmonary arterial hypertension

Dose-response relationship of oral treprostinil for secondary endpoints in the FREEDOM-EV study

A phase 1, single-center, open-label, dose-rising clinical trial to evaluate the pharmacokinetics, safety and tolerability of Treprostinil Inhalation Powder (TreT) in healthy normal volunteers

An open-label, clinical study to evaluate the safety and tolerability of Treprostinil Inhalation Powder (TreT) in patients with pulmonary arterial hypertension (BREEZE Study)

Treatment with Oral Treprostinil Delays Disease Progression in Participants with Pulmonary Arterial Hypertension – Results from the FREEDOM-EV Study

A phase 1, single-center, open-label, dose-rising clinical trial to evaluate the pharmacokinetics, safety and tolerability of Treprostinil Inhalation Powder (TreT) in healthy normal volunteers

Cytokine Profile and Association with Toxicities and Outcome of High-Risk Neuroblastoma Treated with Dinutuximab Immunotherapy on COG ANBL0931

Phase II Trial of Irinotecan/Temozolomide with Dinutuximab/GMCSF (I/T/DIN/GMCSF) in Relapsed/Refractory Neuroblastoma: A Report from The Children’s Oncology Group (COG)

Dinutuximab binds specifically to Disialoganglioside-2

Borg Dyspnea Score Adjusted Six Minute Walk Distance in Pulmonary Arterial Hypertension Clinical Trials

Treatment with Oral Treprostinil is Associated with Improved Survival in Pulmonary Arterial Hypertension Participants from the FREEDOM-EV Study

Treatment with oral treprostinil significantly delays time to clinical worsening in patients with pulmonary arterial hypertension – results from the phase 3, randomized, double-blind, placebo-controlled FREEDOM-EV study

Identifying patients with pulmonary arterial hypertension (PAH) using administrative claims algorithms

Early versus late initiation of treatment with prostacyclin-class therapy in patients with Pulmonary Arterial Hypertension (PAH)

A real-world health insurance claims analysis of oral prostacyclin class therapy utilization and outcomes

Risk stratification Using Noninvasive Parameters: A post hoc analysis of the TRIUMPH and FREEDOM-C2 studies

The economic burden of pulmonary hypertension among patients with chronic obstructive pulmonary disease and interstitial lung disease

Real-World Dosing Characteristics of Parenteral Treprostinil

Risk Scores and Risk-based Stratification of Clinical Worsening Events in PAH Patients Treated with Oral Treprostinil in FREEDOM-EV

Treatment with prostacyclins delays and reduces hospital readmissions among PAH patients

88P Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study

Transition to Oral Treprostinil from Parenteral or Inhaled Treprostinil or as Add-on Therapy in Pediatric Subjects with Pulmonary Arterial Hypertension

A Two-Part, Open-Label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan versus Irinotecan for Second-Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer

The Effect of Treprostinil Dose on Time to All Cause and Pulmonary Arterial Hypertension-Related Hospitalizations

The relationship between non-invasive endpoints and long-term outcomes in pulmonary arterial hypertension: six-minute walk, functional class and brain natriuretic peptide

Predicting adherence to oral treprostinil in patients with pulmonary arterial hypertension

Treatment with prostacyclins reduces hospital readmissions among patients with pulmonary arterial hypertension

The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: a meta-analysis

Combination therapy reduces hospitalizations in patients with pulmonary arterial hypertension

Novel analysis of treprostinil dose-response relationship using weight-normalized dosing

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension Due to Parenchymal Lung Disease (Study RIN-PH-201)

Increasing treprostinil dose reduces annual hospitalization rates and consequent costs in patients with pulmonary arterial hypertension

Stability of treprostinil with diluents and medications

Pharmacokinetics of oral treprostinil in children with pulmonary arterial hypertension

Dosing characteristics of oral treprostinil in real-world clinical practice